Press release header desktop Press release header mobile

Press release

NHS Foundation Trust signs collaboration agreement with Automata to automate laboratories

27th July 2022 Karen Cooper

University Hospital Southampton (UHS) NHS Foundation Trust has signed a commercial collaboration agreement with Automata to develop new applications for laboratory automation technology

Automata is a London based biotech company providing robotic automation solutions to the life sciences industry.  Comprising proprietary hardware, single-platform software and a world-class service, Automata partners with labs to take the hassle out of automation,  empowering them to achieve more reliable results faster than ever before.

Following Automata’s successful implementation of new automated technology as part of the national COVID-19 testing programme response, they are developing their partnership with University Hospital Southampton NHS Foundation Trust (UHS) to explore future clinical use cases in other areas of laboratory medicine.

The partnership aims to optimise Automata’s expertise in lab automation at scale, drawing upon UHS as a development partner and reference site.

Martin Gossling, Head of Commercial Innovation at UHS, said: “A key legacy of delivering saliva testing as part of the national COVID-19 response has been how we can apply the automation of processes on a wider scale across the clinical sector.

“Partnering with Automata has allowed us to combine our knowledge of laboratory work and access to it, with their technological solutions that will ultimately result in more efficient processes at scale that will benefit the NHS and the patients we serve.”

Mostafa ElSayed, CEO & CoFounder Automata adds: “It’s fantastic to be partnering with the NHS to demonstrate how our technology can answer the need for exceptionally reliable solutions that enable scalability, enhance capacity, and empower over-stretched workforces. The whole team at Automata are proud to be helping our amazing NHS  scientists achieve better results faster with worry-free lab automation from Automata Labs.”

About Automata

Automata is a London based biotech company  providing robotic automation solutions to the life sciences industry.

Life Science labs are driving human innovation, yet automation challenges are still holding them back. Their processes are limited by constrained working hours, people conducting repetitive tasks and current lab automation technologies automating only parts of the assay.

With Automata Labs, life science laboratories can increase the reliability, quality and reproducibility of their results. They can shorten turnaround times by scaling capacities, while reducing costs.

Most of all, we enable scientists to spend more time on their analyses, the bedrock for innovation.

Press Release Contact
Karen Cooper

Our socials

Lab Manager Executing Workflow from iPad
The journey to the automated cell biology lab of the future 

Automation has the potential to help achieve high-quality, repeatable results delivered quicker with more usable traceability data than ever before. Start your journey to an automated cell biology lab today with this free guide

Find Automata at the Merck Tech Symposium in New Jersey, this October. Booth 602.
Merck Technology Symposium 2023

Come and find Team Automata at booth 602 CONNECT WITH BOBBY Register TO ATTEND Join us at the 26th Annual Merck Technology Symposium this October. The Symposium will focus on how technology is facilitating scientific decision-making at Merck, a topic we’re passionate about too. We’re looking forward to showcasing how robotically and digitally connecting workflows […]

Meet Automata at Future Labs Live USA in Philadelphia this October
Future Labs Live USA

Team Automata are at Future Labs Live USA, on booth 523 BOOK A MEETING WITH US Register TO ATTEND Future Labs Live USA is taking place in Philadelphia, Pennsylvania this October and we want to meet YOU! Focused on the future of laboratories and featuring presentations and exhibitions from some of the sector’s leading disrupters […]